The DOI matches its Crossref record; 57 of the 59 references it cites were found in a registry or an index.
5-ALA and FDA approval for glioma surgery
Open accessAbstract
The US Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA; Gleolan®; photonamic GmbH and Co. KG) for use as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs) in 2017. This was the first ever optical imaging agent approved as an adjunct for the visualization of malignant tissue during surgery for brain tumors. The approval occurred a decade after European approval and a multicenter, phase III randomized trial which confirmed that surgeons using 5-ALA fluorescence-guided surgery as a surgical adjunct could achieve more complete resections of tumors in HGG patients and better patient outcomes than with conventional microsurgery. Much of the delay in the US FDA approval of 5-ALA stemmed from its conceptualization as a therapeutic and not as an intraoperative imaging tool. We chronicle the challenges encountered during the US FDA approval process to highlight a new standard for approval of intraoperative optical imaging agents in brain tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ALA-PpIX fluorescence-guided tumor resection has been approved for high-grade gliomas and bladder cancers where it shows better surgical outcomes than conventional white light surgery.”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This landmark clinical trial together with additional clinical studies conducted afterward provided enough evidence for the FDA to grant the approval of ALA hydrochloride (Gleolan) in 2017 [43]. The approval allows the use of ALA as an intraoperative imaging probe to facilitate tumor resection in patients with high-grade gliomas (grade III or IV) following a standard oral administration of 20 mg/k”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Because ALA-mediated PpIX fluorescence in tumor tissues is able to provide surgeons with a real-time guide for tumor diagnosis and margin assessment, ALA has been used as an intraoperative probe to facilitate tumor resection [43].”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Self-citationLacroix, M., Abi-Said, D., Fourney, D. R., V, Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E. C., et al. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,162
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
An extent of resection threshold for newly diagnosed glioblastomas
Sanai, N., Polley, M. C., McDermott, M. W., Parsa, A. T., & Berger, M. S. (2011) · Journal of neurosurgery · doi:10.3171/2011.2.jns10998 · Cited by 1,685
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas
WALKER, M. D., Alexander, E., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., Norrell, H., Owens, G., Ransohoff, J., Wilson, C. B., et al. (1978) · Journal of neurosurgery · doi:10.3171/jns.1978.49.3.0333 · Cited by 1,684
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J. E., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,417
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R. G., Vick, N. A., Black, K. L., Sisti, M. B., Brem, S. S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,390
Research works printed but not linked: 1
- Administration USFaD (2006) FDA workshop brain cancer end-points
Cited by
Sorted by citations
Items 301–338 of 338
Protoporphyrin IX delayed fluorescence imaging: a modality for wide range surgical guidance
Pétusseau, A. F., Brůža, P., & Pogue, B. W. (2023) · Molecular-Guided Surgery: Molecules, Devices, and Applications · doi:10.1117/12.2646721
Intraoperative Techniques for Imaging-Guided Surgery of Glioma
Rafie, M. Z., & Norouzi, M. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_159
Theranostics for Oncological Therapy: The Results of World Research and Development Methods
Александрович, Р. Л. (2023) · BIOPHYSICS · doi:10.1134/s0006350923020203
Photodynamic therapy of malignant brain tumors (literature review
Shakhmanaeva, A. U.-K., Kozlikina, E. I., Трифонов, И. С., & Levchenko, O. V. (2023) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2311-11
Manrique-Guzmán, S., Larocque-Guzman, C. M., Revilla-Pacheco, F. R., Herrada-Pineda, T., Sánchez-Torres, C., Santa-Ana, J. S., Loyo-Varela, M., Acuña-Macouzet, A., & Guerrero-Hernandez, M. (2024) · doi:10.22541/au.170668369.92049839/v1
Suresh Vishnu, A. (2023) · Neurosurgery Cases and Reviews · doi:10.23937/2643-4474/1710147
Theranostics for oncological therapy: results from worldwide research and the paths of development
Александрович, Р. Л. (2023) · Биофизика · doi:10.31857/s0006302923020187
Ochoa, M., Reed, M. S., Zeng, W., Poore, S. O., Hasan, T. G., & Pogue, B. W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.27.615461
Nakanishi, N., Kaikita, K., Oimatsu, Y., Ishii, M., Kuyama, N., Arima, Y., Araki, S., Nakamura, T., Yamamoto, E., & Tsujita, K. (2024) · Heart and Vessels · doi:10.1007/s00380-024-02480-9
Zdubek, A., Maliszewska, I. H., Grabowiecka, A., Kowalczyk, R., & Turek, B. (2024) · ACS Omega · doi:10.1021/acsomega.4c07696
Modern possibilities of treating brain tumors: intraoperative technologies in neurooncology
Nafikov, A. I., Minnigaleev, R. I., Yarullina, E. R., Magomedova, E. M., Soboleva, K. G., Sobolev, M. M., Egamova, O. R., Kirillova, Y. A., Arutyunyan, A. A., Tokhova, F. A., et al. (2025) · Journal of clinical practice · doi:10.17816/clinpract643543
Li, C., & Fan, Y.-D. (2025) · Springer eBooks · doi:10.1007/978-981-96-6875-5_12
Ibrahim, M. A. A., Mahmoud, A. H. H., Rady, A. S. M., Sidhom, P. A., Mohamed, L. A., Khan, S., & Rady, A. M. (2025) · Chemical Physics Letters · doi:10.1016/j.cplett.2025.142348
Huq, S., Kallos, J. A., Boggs, K., Diamond, K., Scanlon, S. E., Bin-Alamer, O., Rivera, D., Pearce, T. M., & Hadjipanayis, C. G. (2025) · Operative Neurosurgery · doi:10.1227/ons.0000000000001798
Self-citationImage-guided surgery of cancer
Sharma, R. K., & Rosenthal, E. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22253-5.00019-4
Microscopy: Enhancing Visualization in the Surgical Challenge
Rosen, K., Bander, E. D., & Schwartz, T. H. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009597852.016
Computer Science: The Computer as a Neurosurgical Tool
Koo, A. B., & King, J. D. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009597852.015
Tian, X., Sun, B., Cheng, H., Hao, X., Sun, G., Hao, J., & Chen, L. (2025) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2025.105316
Boekestijn, I., van Oosterom, M. N., Dell’Oglio, P., van Velden, F. H. P., Pool, M., Maurer, T., Rietbergen, D. D. D., Buckle, T., & van Leeuwen, F. W. B. (2022) · Figshare · doi:10.6084/m9.figshare.21019380
Application and prospects of photodynamic therapy in the treatment of brain glioma
Yang, F., Zhou, L., Xu, Y., & Hu, S. (2025) · Med-X · doi:10.1007/s44258-025-00073-3
Fulbert, C. (2021) · theses.fr (ABES) · doi:10.70675/8d05f8f9z73edz448fz8deaz7335900a1106
Hétérogénéité et plasticité de l’intégrine α5 dans les cellules souches de glioblastome
Messé, M. (2023) · theses.fr (ABES) · doi:10.70675/5bee424dz19e3z4870zb9b1z927eaa272304
Trioën, C. (2024) · theses.fr (ABES) · doi:10.70675/7c132518z8997z4d01z8084z87c06a661e5a
Le mimétique de SMAC GDC-0152 : un nouvel immunomodulateur dans les glioblastomes
Snacel-Fazy, E. (2023) · theses.fr (ABES) · doi:10.70675/7e5e377fzaaa9z4f1dzbde6z9586007f6c3d
Recent Advances in Nanomedicine for Targeted Phototherapy in Head and Neck Cancer
Liu, H., Chen, L., Li, W., Wu, L., Xia, Z., Wu, Y., Huang, Y., Gu, S., Zhang, J., & Shen, Z. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s596902
Meer, E. A., Pekmezci, M., Hodgson, N. M., Lu, J., & Winn, B. J. (2026) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000003230
Zhang, K. Y., Chen, Q., Huang, Q., Qi, X., Qin, Y., Wang, D., Zhu, R., Wang, G., & Ma, X. (2026) · ACS Omega · doi:10.1021/acsomega.6c05165
de Lima, F. B. F., Figueiredo, H. P. G., Faria, B. C. D., Albuquerque, J. P. S., de Almeida, J. C., Nunes, M. B., Miranda, E. C., Amaro, A. P., Ferreira, T. R., & Dellaretti, M. (2026) · Arquivos Brasileiros de Neurocirurgia Brazilian Neurosurgery · doi:10.1055/s-0046-1823000
Mischkulnig, M., Reichert, D., Wightman, L., Roth, V., Hoelz, M., Klang, A., Körner, L., Kiesel, B., Vejzović, D., Erkkilä, M. T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-62969-3
Shangguan, P., Zhong, Y., Wu, H., Liu, Y., Wang, G., Qi, C., Ouyang, J., Zhao, S., Wang, X., Yin, J., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aeb8054
Yi, M., Wang, L., Chen, Y., Li, J., Weng, X., Zhang, C., Chen, D., Liu, L., Vasyutinskii, O. S., Lin, F., et al. (2026) · Applied Physics Reviews · doi:10.1063/5.0337865
Chen, G., Li, C., Muhammad, P., Wang, Y., Yuan, K., Pan, P., Hou, X., Wang, Y., Wang, Y., Pang, D., et al. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103146
Price, C. G., Sanders, H. S., Barreto, A. F. D. A., Talavera, D., Ramirez, A. L., Rho, S., O’Sullivan, T. D., & Smith, B. D. (2026) · Biomedical Optics Express · doi:10.1364/boe.611984
5-Aminolevulinic Acid–mediated Photodynamic Therapy for Glioblastoma
Reyes, J. S., Bouras, A., Huq, S., Colán, J. A., Casillo, S. M., & Hadjipanayis, C. G. (2026) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.09.001
Self-citation
Metadata
- Authors
- Hadjipanayis, C. G., & Stummer, W.
- Affiliations
- University Hospital Münster (DE)
- Venue
- Journal of Neuro-Oncology
- Published
- 2019-01-14
- Volume
- 141
- Issue
- 3
- Pages
- 479-486
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- PMC
- PMC6445645
- OpenAlex
- W2910072132
- Cited by
- 338
- References
- 59
- Citations by year
- 2026: 19 · 2025: 53 · 2024: 60 · 2023: 51 · 2022: 59 · 2021: 52 · 2020: 32 · 2019: 12
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neuro-Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Merck
- Novocure
- Arbor Pharmaceuticals
- National Cancer Institute (R01CA176659)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Optical Imaging and Spectroscopy Techniques
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Keywords
- 5-aminolevulinic acid, fluorescence-guided surgery, high-grade glioma, FDA drug approval, brain tumor surgery, tumor resection completeness, regulatory challenges
- MeSH terms
- Aminolevulinic Acid, Brain Neoplasms, Fluorescent Dyes, Glioma, Humans, United States, United States Food and Drug Administration, Drug Approval, Surgery, Computer-Assisted, Optical Imaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
